BRAF and basal cell carcinoma: Regarding the rising related topics, pathological genes and monoclonal antibodies, including “BRAF,” “Ipilimumab,” “Nivolumab,” “Pembrolizumab,” and “Vemurafenib,” exhibited an increase over 5,000%, followed by associated diseases, including the topics “Squamous cell carcinoma” (n = 500%), “Basal-cell carcinoma” (n = 400%), “Melanocytic nevus” (n = 350%), and “Nevus” (n = 250%).